Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2016 Jun 23

PMID 27330105

Citations 18

Authors

Scott M Haake

Jamie D Weyandt

W Kimryn Rathmell

Affiliations

Soon will be listed here.

Abstract

The renal cell carcinomas (RCC), clear cell, papillary, and chromophobe, have recently undergone an unmatched genomic characterization by The Cancer Genome Atlas. This analysis has revealed new insights into each of these malignancies and underscores the unique biology of clear cell, papillary, and chromophobe RCC. Themes that have emerged include distinct mechanisms of metabolic dysregulation and common mutations in chromatin modifier genes. Importantly, the papillary RCC classification encompasses a heterogeneous group of diseases, each with highly distinct genetic and molecular features. In conclusion, this review summarizes RCCs that represent a diverse set of malignancies, each with novel biologic programs that define new paradigms for cancer biology. Mol Cancer Res; 14(7); 589-98. ©2016 AACR.

Citing Articles

Papillary Renal Cell Carcinoma: Current Evidence and Future Directions.

Jang A, Hobeika C, Gupta S Kidney Cancer. 2025; 8(1):61-79.

PMID: 40027140 PMC: 11870658. DOI: 10.3233/kca-230027.

Clinical and molecular prognostic nomograms for patients with papillary renal cell carcinoma.

Wang X Discov Oncol. 2024; 15(1):780.

PMID: 39692801 PMC: 11655765. DOI: 10.1007/s12672-024-01669-8.

Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression.

Onagi A, Sugimoto K, Kobayashi M, Sato Y, Kobayashi Y, Yaginuma K Cell Commun Signal. 2024; 22(1):588.

PMID: 39639312 PMC: 11619122. DOI: 10.1186/s12964-024-01964-5.

Differential expression of ORAI channels and STIM proteins in renal cell carcinoma subtypes: implications for metastasis and therapeutic targeting.

Kim J, Hwang K, Oh J, Kim S, Lee M, Lee T Korean J Physiol Pharmacol. 2024; 29(1):33-43.

PMID: 39482235 PMC: 11694002. DOI: 10.4196/kjpp.24.126.

Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.

Hong S, Lee Y, Jang E, Hwang H, Kim E, Son D Int J Mol Sci. 2024; 25(1).

PMID: 38203388 PMC: 10779260. DOI: 10.3390/ijms25010216.

References

Huang F, Hodis E, Xu M, Kryukov G, Chin L, Garraway L . Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122):957-9. PMC: 4423787. DOI: 10.1126/science.1229259. View

Li B, Qiu B, Lee D, Walton Z, Ochocki J, Mathew L . Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 2014; 513(7517):251-5. PMC: 4162811. DOI: 10.1038/nature13557. View

Ramphal R, Pappo A, Zielenska M, Grant R, Ngan B . Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am J Clin Pathol. 2006; 126(3):349-64. DOI: 10.1309/98YE9E442AR7LX2X. View

. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161(7):1681-96. PMC: 4580370. DOI: 10.1016/j.cell.2015.05.044. View

. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499(7456):43-9. PMC: 3771322. DOI: 10.1038/nature12222. View

Isaacs J, Jung Y, Mole D, Lee S, Torres-Cabala C, Chung Y . HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005; 8(2):143-53. DOI: 10.1016/j.ccr.2005.06.017. View

Klatte T, Pantuck A, Said J, Seligson D, Rao N, Larochelle J . Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009; 15(4):1162-9. DOI: 10.1158/1078-0432.CCR-08-1229. View

. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417):519-25. PMC: 3466113. DOI: 10.1038/nature11404. View

Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M . Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007; 69(2):230-5. DOI: 10.1016/j.urology.2006.09.052. View

10.

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

11.

Hoadley K, Yau C, Wolf D, Cherniack A, Tamborero D, Ng S . Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158(4):929-944. PMC: 4152462. DOI: 10.1016/j.cell.2014.06.049. View

12.

Joshi S, Tolkunov D, Aviv H, Hakimi A, Yao M, Hsieh J . The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep. 2015; 13(9):1895-908. PMC: 4779191. DOI: 10.1016/j.celrep.2015.10.059. View

13.

Yang X, Tan M, Kim H, Ditlev J, Betten M, Png C . A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005; 65(13):5628-37. DOI: 10.1158/0008-5472.CAN-05-0533. View

14.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

15.

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

16.

Tannir N, Jonasch E, Albiges L, Altinmakas E, Ng C, Matin S . Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2015; 69(5):866-74. PMC: 4879109. DOI: 10.1016/j.eururo.2015.10.049. View

17.

Brooks S, Brannon A, Parker J, Fisher J, Sen O, Kattan M . ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014; 66(1):77-84. PMC: 4058355. DOI: 10.1016/j.eururo.2014.02.035. View

18.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

19.

Toro J, Nickerson M, Wei M, Warren M, Glenn G, Turner M . Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003; 73(1):95-106. PMC: 1180594. DOI: 10.1086/376435. View

20.

Kinch L, Grishin N, Brugarolas J . Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell. 2011; 20(4):418-20. PMC: 3226726. DOI: 10.1016/j.ccr.2011.10.005. View